slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 42,121-42,150
Pages 2,019
Rows per page 30
Component
42,121-42,150 of 60,568
27
Uses a 'VS' structure to frame the incumbent management as value-creators and the activist investor as a destroyer of value.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
28
Uses a visual 'X' marker to contrast the offer against internal valuation metrics.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
29
Uses a contrast-pair structure to systematically dismantle opponent claims.Nano Dimension | Shareholder Engagement Presentation Deck | 34 slides · Nano Dimension
Shareholder letter Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
22
Nextdoor | Investor Presentation Deck | 34 slidesNextdoor | Investor Presentation Deck | 34 slides · Nextdoor
Pitch deck Investor relations 1 hit
31
Includes page number 31 in top right corner.Nextdoor | Investor Presentation Deck | 34 slides · Nextdoor
Pitch deck Investor relations 1 hit
33
Standard financial reconciliation table format.Nextdoor | Investor Presentation Deck | 34 slides · Nextdoor
Pitch deck Investor relations 1 hit
34
Nextdoor | Investor Presentation Deck | 34 slidesNextdoor | Investor Presentation Deck | 34 slides · Nextdoor
Pitch deck Investor relations 1 hit
08
The table lists specific line items like D&A, share-based payments, and tax expenses to bridge net income to Adjusted EBITDA.Nexters | Results Presentation Deck | 8 slides · GDEV Inc.
Conference presentation Investor relations 1 hit
08
The slide details a capital raise structure involving senior secured notes and warrants.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
06
The slide uses a map of California to visualize station locations and a table to provide granular project details.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
10
Includes footnotes regarding restricted cash, FFI acquisition, share registration, and adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
11
Includes footnotes detailing stock-based compensation components.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
16
Includes a footnote regarding adjustments for Q4 2022 and Q1 2023.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
17
The table includes a footnote regarding adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
18
The table includes a footnote regarding Q4 2022 and Q1 2023 adjustments related to Romeo Power.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data presentation for NVL-520.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a timeline-style layout to represent drug development stages.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit